These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966 [TBL] [Abstract][Full Text] [Related]
24. Psychiatric symptoms with initiation of carbidopa-levodopa treatment. Lin JT; Ziegler DK Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518 [TBL] [Abstract][Full Text] [Related]
25. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt JG; Woodward WR; Anderson JL Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849 [TBL] [Abstract][Full Text] [Related]
26. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. Modi NB; Mittur A; Rubens R; Khanna S; Gupta S Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758 [TBL] [Abstract][Full Text] [Related]
27. Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study. Fasano A; Gurevich T; Jech R; Kovács N; Svenningsson P; Szász J; Parra JC; Bergmann L; Johnson A; Sanchez-Soliño O; Tang Z; Vela-Desojo L Mov Disord; 2021 Aug; 36(8):1853-1862. PubMed ID: 33908647 [TBL] [Abstract][Full Text] [Related]
28. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Dhall R; Kreitzman DL Neurology; 2016 Apr; 86(14 Suppl 1):S13-24. PubMed ID: 27044646 [TBL] [Abstract][Full Text] [Related]
29. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M; Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809 [TBL] [Abstract][Full Text] [Related]
30. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism. Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861 [TBL] [Abstract][Full Text] [Related]
31. Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naïve older patients with Parkinson's disease: A before-after study. Arai M Neuro Endocrinol Lett; 2012; 33(1):34-6. PubMed ID: 22467109 [TBL] [Abstract][Full Text] [Related]
32. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait. Cossu G; Ricchi V; Pilleri M; Mancini F; Murgia D; Ricchieri G; Mereu A; Melis M; Antonini A Neurol Sci; 2015 Sep; 36(9):1683-6. PubMed ID: 25939726 [TBL] [Abstract][Full Text] [Related]
33. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease. Lieberman AN; Gopinathan G; Neophytides A; Pasternack P N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386 [No Abstract] [Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973 [TBL] [Abstract][Full Text] [Related]
35. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635 [TBL] [Abstract][Full Text] [Related]
36. [Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease]. Fernandez-Pajarin G; Ares-Pensado B; Sesar A; Iglesias-Canle J; Masa-Vazquez L; Castro A Rev Neurol; 2018 Jul; 67(1):1-5. PubMed ID: 29923594 [TBL] [Abstract][Full Text] [Related]
37. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015 [TBL] [Abstract][Full Text] [Related]
38. Allergy to Carbidopa. Cansino-Torres MA; Sandoval-Rodríguez V; Sáenz-Farret M; Zúñiga-Ramírez C Clin Neuropharmacol; 2018; 41(2):75-79. PubMed ID: 29432287 [TBL] [Abstract][Full Text] [Related]
39. Use of carbidopa-levodopa in a patient with hydrocephalus and frozen movement. Aggarwal S; Childers MK; Jimenez D Brain Inj; 1997 Nov; 11(11):831-6. PubMed ID: 9354260 [TBL] [Abstract][Full Text] [Related]